- Home
- SNBR vs DMAC Comparison
SNBR vs DMAC Comparison
Compare SNBR & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNBR
- DMAC
- Stock Information
- Founded
- SNBR 1987
- DMAC 2000
- Country
- SNBR United States
- DMAC United States
- Employees
- SNBR N/A
- DMAC N/A
- Industry
- SNBR Home Furnishings
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- SNBR Consumer Discretionary
- DMAC Health Care
- Exchange
- SNBR Nasdaq
- DMAC Nasdaq
- Market Cap
- SNBR 154.1M
- DMAC 178.0M
- IPO Year
- SNBR 1998
- DMAC N/A
- Fundamental
- Price
- SNBR $8.28
- DMAC $5.05
- Analyst Decision
- SNBR Hold
- DMAC Strong Buy
- Analyst Count
- SNBR 2
- DMAC 4
- Target Price
- SNBR $9.00
- DMAC $10.75
- AVG Volume (30 Days)
- SNBR 603.3K
- DMAC 495.0K
- Earning Date
- SNBR 07-30-2025
- DMAC 08-06-2025
- Dividend Yield
- SNBR N/A
- DMAC N/A
- EPS Growth
- SNBR N/A
- DMAC N/A
- EPS
- SNBR N/A
- DMAC N/A
- Revenue
- SNBR $1,605,108,000.00
- DMAC N/A
- Revenue This Year
- SNBR N/A
- DMAC N/A
- Revenue Next Year
- SNBR $4.27
- DMAC N/A
- P/E Ratio
- SNBR N/A
- DMAC N/A
- Revenue Growth
- SNBR N/A
- DMAC N/A
- 52 Week Low
- SNBR $4.48
- DMAC $3.19
- 52 Week High
- SNBR $20.75
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- SNBR 55.18
- DMAC 66.86
- Support Level
- SNBR $6.45
- DMAC $3.65
- Resistance Level
- SNBR $9.41
- DMAC $5.25
- Average True Range (ATR)
- SNBR 0.73
- DMAC 0.42
- MACD
- SNBR 0.17
- DMAC 0.14
- Stochastic Oscillator
- SNBR 61.82
- DMAC 88.06
About SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.